Costanzo-Nordin M R, Hubbell E A, O'Sullivan E J, Johnson M R, Mullen G M, Heroux A L, Kao W G, McManus B M, Pifarre R, Robinson J A
Department of Medicine, Loyola University of Chicago, Maywood.
Circulation. 1992 Nov;86(5 Suppl):II242-50.
Photopheresis is a technique in which reinfusion of mononuclear cells exposed to UV-A light ex vivo after in vivo treatment with 8-methoxypsoralen initiates host-immunosuppressive responses.
To determine if photopheresis safely reverses International Society for Heart and Lung Transplantation (ISHLT) rejection grades 2, 3A, and 3B without hemodynamic compromise, 16 heart transplant patients with ISHLT rejection grades 2, 3A, and 3B were randomized to photopheresis or corticosteroid therapy. The average number of mononuclear cells treated with each photopheresis procedure was 9.8 +/- 9.1 x 10(9) (mean +/- SD). Photopheresis and corticosteroids reversed eight of nine and seven of seven episodes of rejection, respectively. The median time from initiation of treatment to rejection reversal was 25 days (range, 6-67 days) in the photopheresis group and 17 days (range, 8-33 days) in the corticosteroid group. Hemodynamics were normal before either treatment and did not change after reversal of rejection. No adverse reactions occurred with photopheresis, and all patients in either treatment group are alive.
These preliminary, short-term results in prospectively randomized patients indicate that photopheresis may be as effective as corticosteroids for treating ISHLT rejection grades 2, 3A, and 3B. The apparently low toxicity and potential efficacy of photopheresis warrant further analysis of its role in the prevention and treatment of heart transplant rejection.
光化学疗法是一种技术,即在体内用8-甲氧基补骨脂素治疗后,将体外暴露于紫外线A光的单核细胞回输,引发宿主免疫抑制反应。
为了确定光化学疗法能否在不影响血流动力学的情况下安全逆转国际心肺移植学会(ISHLT)2级、3A级和3B级排斥反应,16例ISHLT 2级、3A级和3B级排斥反应的心脏移植患者被随机分为光化学疗法组或皮质类固醇治疗组。每次光化学疗法治疗的单核细胞平均数量为9.8±9.1×10⁹(平均值±标准差)。光化学疗法和皮质类固醇分别逆转了9次排斥反应中的8次和7次排斥反应中的7次。光化学疗法组从开始治疗到排斥反应逆转的中位时间为25天(范围6 - 67天),皮质类固醇组为17天(范围8 - 33天)。两种治疗前血流动力学均正常,排斥反应逆转后也未改变。光化学疗法未出现不良反应,两个治疗组的所有患者均存活。
这些前瞻性随机分组患者的初步短期结果表明,光化学疗法在治疗ISHLT 2级、3A级和3B级排斥反应方面可能与皮质类固醇一样有效。光化学疗法明显较低的毒性和潜在疗效值得进一步分析其在心脏移植排斥反应预防和治疗中的作用。